EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, Inc., will give a presentation titled “Translational kinetic biomarkers to enable the development of HTT-lowering therapies” at the CHDI Foundation’s 9th Annual Huntington's Disease Therapeutics Conference, taking place February 27th in Palm Springs, California https://www.regonline.com/builder/site/default.aspx?EventID=1348832 .
Dr. Fanara’s presentation will be part of the session titled “Huntingtin Lowering Biomarkers” scheduled to take place Thursday, from 9:00 AM to 12:20 PM. The session will be chaired by Roger Cachope, M.D., M.S., Director, Systems Neurobiology for the CHDI Foundation, and Lamya Shihabuddin, Ph.D., Senior Director of Neuroscience the Genzyme Corporation.
About KineMed, Inc.
KineMed is a commercial-stage company focused on applying its proprietary biomarker platform technology to drug development with BioPharma partners, prescription and non-prescription medical diagnostics and the pairing of its own drugs with its diagnostic biomarker tests.
KineMed’s diagnostic biomarker tests directly measure the rate of activity of critical biological pathways that cause or modify disease. This is done by measuring through a single sample the flux, or rate of production and destruction over a period of time, of the key molecules involved in these disease-modifying biological processes, using proprietary mass spectrometric-based methods. KineMed believes that measuring molecular flux rates can provide interpretable information that is predictive for clinically meaningful endpoints for an individual patient and that predictive, personalized data about a patient that can guide healthcare decisions. As a result, KineMed believes that its biomarkers can be used to make drug development more efficient and to guide healthcare decisions by physicians and wellness decisions by consumers. Building on a legacy of collaborative relationships and experience in human disease research in drug development settings, KineMed is currently focused on commercializing biomarker tests and advancing drug leads in six areas: muscle biology, fibrotic diseases, cancer, neurodegenerative diseases, cardiometabolic diseases and skin care.
For more information about KineMed, please visit: www.kinemed.com